Nouscom Raises €120 Million for a Cancer-Prevention Trial in Lynch Syndrome
Nouscom has raised €120 million (around $135 million) in a Series D round to fund a global trial of NOUS-209 in carriers of hereditary Lynch syndrome.
Nouscom raised €120 million, approximately $135 million, in an oversubscribed Series D funding round co-led by M Ventures and Revelation Partners, according to the Startup.eu platform.
Neva SGR, Angelini Industries, and the European Investment Bank participated in the round, alongside all existing investors.
The proceeds from the round will be used to fund a global registration-enabling trial for NOUS-209 in carriers of hereditary Lynch syndrome.
Lynch syndrome is associated with an increased risk of developing several types of cancer, making the trial target a high-risk population that requires close monitoring.
What do these terms mean?
Series D: A late-stage funding round typically used to expand business operations or fund large-scale trials prior to an IPO or acquisition.
Registration-enabling trial: A clinical trial designed to produce sufficient data for submitting a treatment approval application to regulatory authorities.
Lynch syndrome: A genetic condition that increases the likelihood of developing several types of cancer, requiring regular medical follow-up.
Weekly Newsletter
Read between the lines before everyone else. Decode the most important economic, tech, and decision-maker movements in the region.. in 5 minutes every Saturday.
